key: cord-0682961-j1hc5hfs
authors: Rocco, Joseph M.; Hammoud, Dima A.; Allen, Clint T.; Galindo, Frances; Laidlaw, Elizabeth; Sereti, Irini
title: Trismus and voice change after starting tuberculosis treatment
date: 2021-10-08
journal: IDCases
DOI: 10.1016/j.idcr.2021.e01307
sha: b50702b218eeff5aaeb2edb99665bf57991b2b7b
doc_id: 682961
cord_uid: j1hc5hfs

nan

A 29-year-old man with perinatally-acquired human immunodeficiency virus (HIV) and newly diagnosed disseminated tuberculosis on treatment presented one month after restarting antiretroviral therapy (ART) with fevers, nasal obstruction, and change in voice. He was born in Malawi and moved to the United States at 10-years old with no additional travel outside the country. His HIV was well-controlled until he lost his job and health insurance at the start of the COVID-19 pandemic. Subsequently, he developed bilateral, upper lobe pneumonia with sputum culture growing Mycobacterium tuberculosis. He was treated for two-months with anti-mycobacterials prior to restarting ART.

On presentation to the National Institutes of Health, informed consent was obtained, and he enrolled on clinical trial NCT02147405. He was febrile with bilateral cervical lymphadenopathy and unable to fully open his mouth due to trismus. Laboratory studies revealed a CRP 117.8 mg/L, CD4+ T cell count 126 cells/mcL and a four log HIV viral load reduction since starting ART. Positron emission tomography (PET) scan demonstrated multiple fluid collections with peripheral uptake of FDG consistent with inflamed necrotic lymph nodes ( Fig. 1A and B) . Blood, sputum, and lymph node aspirate cultures were negative. Prednisone was initiated for immune reconstitution inflammatory syndrome (IRIS), but follow-up computed tomography (CT) showed no appreciable decrease in the size of the necrotic lymph nodes (Fig. 1C) . He underwent multiple incision and drainage procedures and his nasal obstruction and voice changes subsequently improved with markedly decreased size of the cervical lymph nodes (Fig. 1D ). Acid fast staining consistently showed heavy organism burden, but all mycobacterial cultures remained negative at six-weeks. After five-months of prednisone with anti-mycobacterial therapy, his inflammatory symptoms resolved.

Tuberculosis-IRIS can cause lymph node necrosis throughout the body and may involve unique locations [1] . Despite heavy burden of mycobacteria on acid-fast staining, no viable organisms were isolated, highlighting this inflammatory process is antigen driven and does not require replicating pathogens [2] . When large necrotic lymph nodes are present, incision and drainage can be safely performed to decrease antigen burden. Treatment otherwise consists primarily of steroids while continuing anti-mycobacterials and ART until inflammatory symptoms improve [1] . Infliximab has also been used successfully to control IRIS-related inflammation in refractory cases [3] . 

This study was approved by the National Institutes of Health Institutional Review Board, IRB number: 20I0111 

Tuberculosis-immune reconstitution inflammatory syndrome

Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis

A paradoxical treatment for a paradoxical condition: infliximab use in three cases of mycobacterial IRIS

Funding for this study was provided in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

All authors declare no conflicts of interest.